Legend Biotech Corp
NASDAQ:LEGN

Watchlist Manager
Legend Biotech Corp Logo
Legend Biotech Corp
NASDAQ:LEGN
Watchlist
Price: 21.87 USD -0.64%
Market Cap: 4B USD

Net Margin
Legend Biotech Corp

-26.4%
Current
-152%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-26.4%
=
Net Income
-240m
/
Revenue
909m

Net Margin Across Competitors

No Stocks Found

Legend Biotech Corp
Glance View

Legend Biotech Corp., an emerging leader in the biotechnology arena, has carved out a niche at the forefront of cellular therapeutics, focusing on transforming cancer treatment paradigms. Born out of the ambition to explore innovative medical frontiers, Legend Biotech embarked on a mission to develop Car-T cell therapies—a personalized form of immunotherapy that employs genetically altered T-cells to target and eradicate cancer cells. With its signature product, Carvykti (ciltacabtagene autoleucel), Legend Biotech has been making waves in the oncology sector. By redirecting the body's own immune system against multiple myeloma, a rare and challenging form of cancer, the company has demonstrated the potential to achieve deep and lasting remissions, bringing hope where conventional treatments may fall short. The financial model of Legend Biotech is driven by strategic partnerships, extensive research and development initiatives, and successful navigation through complex regulatory landscapes. Partnering with Johnson & Johnson's subsidiary Janssen Biotech, the collaboration capitalizes on their combined expertise to advance Car-T technology. Revenues primarily flow from milestone payments upon achieving specific developmental goals, along with royalties derived from global sales of their breakthrough treatments. By investing heavily in R&D and ensuring a robust pipeline of therapeutic candidates, Legend Biotech positions itself for sustainable growth, striving to extend their innovative treatments to a broader range of cancers and, eventually, achieve profitability through expanded indications and market reach.

LEGN Intrinsic Value
76.99 USD
Undervaluation 72%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-26.4%
=
Net Income
-240m
/
Revenue
909m
What is the Net Margin of Legend Biotech Corp?

Based on Legend Biotech Corp's most recent financial statements, the company has Net Margin of -26.4%.

Back to Top